Investment Analysts’ Recent Ratings Updates for PTC Therapeutics (PTCT)

Several analysts have recently updated their ratings and price targets for PTC Therapeutics (NASDAQ: PTCT):

• 12/15/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – PTC Therapeutics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/1/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – PTC Therapeutics was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating. They now have a $91.00 price target on the stock, up previously from $82.00.
• 11/25/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – PTC Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – PTC Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/5/2025 – PTC Therapeutics had its “hold” rating reaffirmed by analysts at Cowen Inc.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $44.00 to $50.00. They now have a “sell” rating on the stock.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Wells Fargo & Company from $73.00 to $93.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Barclays PLC from $46.00 to $68.00. They now have an “equal weight” rating on the stock.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Citigroup Inc. from $50.00 to $75.00. They now have a “neutral” rating on the stock.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at TD Cowen from $50.00 to $63.00. They now have a “hold” rating on the stock.
• 11/5/2025 – PTC Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an “outperform” rating on the stock.
• 10/28/2025 – PTC Therapeutics had its price target raised by analysts at Jefferies Financial Group Inc. from $63.00 to $77.00. They now have a “buy” rating on the stock.

Insider Activity

In other PTC Therapeutics news, CEO Matthew B. Klein sold 3,428 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $79.07, for a total value of $271,051.96. Following the completion of the sale, the chief executive officer directly owned 349,964 shares in the company, valued at $27,671,653.48. This represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Neil Gregory Almstead sold 71,928 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $83.44, for a total value of $6,001,672.32. Following the completion of the transaction, the insider directly owned 100,625 shares in the company, valued at $8,396,150. This represents a 41.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 337,822 shares of company stock worth $25,189,267 over the last ninety days. 5.50% of the stock is currently owned by company insiders.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.